These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 15206659)
1. Paroxetine treatment of depression with posttraumatic stress disorder: effects on autonomic reactivity and cortisol secretion. Tucker P; Beebe KL; Burgin C; Wyatt DB; Parker DE; Masters BK; Nawar O J Clin Psychopharmacol; 2004 Apr; 24(2):131-40. PubMed ID: 15206659 [TBL] [Abstract][Full Text] [Related]
2. Alterations in stress reactivity after long-term treatment with paroxetine in women with posttraumatic stress disorder. Vermetten E; Vythilingam M; Schmahl C; DE Kloet C; Southwick SM; Charney DS; Bremner JD Ann N Y Acad Sci; 2006 Jul; 1071():184-202. PubMed ID: 16891570 [TBL] [Abstract][Full Text] [Related]
3. Prospective Study of the Effectiveness of Paroxetine on the Onset of Posttraumatic Stress Disorder, Depression, and Health and Functional Outcomes After Trauma. Borrelli J; Starr A; Downs DL; North CS J Orthop Trauma; 2019 Feb; 33(2):e58-e63. PubMed ID: 30277987 [TBL] [Abstract][Full Text] [Related]
4. Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder. Tucker P; Smith KL; Marx B; Jones D; Miranda R; Lensgraf J J Clin Psychopharmacol; 2000 Jun; 20(3):367-72. PubMed ID: 10831026 [TBL] [Abstract][Full Text] [Related]
5. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. Bonne O; Gill JM; Luckenbaugh DA; Collins C; Owens MJ; Alesci S; Neumeister A; Yuan P; Kinkead B; Manji HK; Charney DS; Vythilingam M J Clin Psychiatry; 2011 Aug; 72(8):1124-8. PubMed ID: 21208596 [TBL] [Abstract][Full Text] [Related]
6. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. Marshall RD; Schneier FR; Fallon BA; Knight CB; Abbate LA; Goetz D; Campeas R; Liebowitz MR J Clin Psychopharmacol; 1998 Feb; 18(1):10-8. PubMed ID: 9472837 [TBL] [Abstract][Full Text] [Related]
7. Emotional stress and heart rate variability measures associated with cardiovascular risk in relocated Katrina survivors. Tucker P; Pfefferbaum B; Jeon-Slaughter H; Khan Q; Garton T Psychosom Med; 2012; 74(2):160-8. PubMed ID: 22286851 [TBL] [Abstract][Full Text] [Related]
8. Cortisol stress response in post-traumatic stress disorder, panic disorder, and major depressive disorder patients. Wichmann S; Kirschbaum C; Böhme C; Petrowski K Psychoneuroendocrinology; 2017 Sep; 83():135-141. PubMed ID: 28623762 [TBL] [Abstract][Full Text] [Related]
9. Age effects on cortisol levels in depressed patients with and without comorbid post-traumatic stress disorder, and healthy volunteers. Sher L; Oquendo MA; Galfalvy HC; Cooper TB; Mann JJ J Affect Disord; 2004 Oct; 82(1):53-9. PubMed ID: 15465576 [TBL] [Abstract][Full Text] [Related]
10. Enhanced cortisol suppression in response to dexamethasone administration in traumatized veterans with and without posttraumatic stress disorder. de Kloet CS; Vermetten E; Heijnen CJ; Geuze E; Lentjes EG; Westenberg HG Psychoneuroendocrinology; 2007 Apr; 32(3):215-26. PubMed ID: 17296270 [TBL] [Abstract][Full Text] [Related]
11. A Double-Blind, Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder and Comorbid Depression. Ramaswamy S; Driscoll D; Reist C; Smith LM; Albers LJ; Rose J; Nguyen L; Monga V; Doria R; Hollifield M Prim Care Companion CNS Disord; 2017 Aug; 19(4):. PubMed ID: 28858440 [TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine and psychophysiologic responses in PTSD: a symptom provocation study. Liberzon I; Abelson JL; Flagel SB; Raz J; Young EA Neuropsychopharmacology; 1999 Jul; 21(1):40-50. PubMed ID: 10379518 [TBL] [Abstract][Full Text] [Related]
13. Altered cortisol awakening response in posttraumatic stress disorder. Wessa M; Rohleder N; Kirschbaum C; Flor H Psychoneuroendocrinology; 2006 Feb; 31(2):209-15. PubMed ID: 16154709 [TBL] [Abstract][Full Text] [Related]
14. Paroxetine in the treatment of post traumatic stress disorder: our experiences. Kucukalić A; Bravo-Mehmedbasić A; Dzubur-Kulenović A Bosn J Basic Med Sci; 2008 Feb; 8(1):76-9. PubMed ID: 18318677 [TBL] [Abstract][Full Text] [Related]
15. Sertralilne, paroxetine and venlafaxine in refugee post traumatic stress disorder with depression symptoms. Smajkić A; Weine S; Durić-Bijedić Z; Boskailo E; Lewis J; Pavković I Med Arh; 2001; 55(1 Suppl 1):35-8. PubMed ID: 11795192 [TBL] [Abstract][Full Text] [Related]
16. Quality of Life and Functioning in Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder After Treatment With Citalopram Monotherapy. Steiner AJ; Boulos N; Mirocha J; Wright SM; Collison KL; IsHak WW Clin Neuropharmacol; 2017; 40(1):16-23. PubMed ID: 27764051 [TBL] [Abstract][Full Text] [Related]
17. Paroxetine: an update of its use in psychiatric disorders in adults. Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL Drugs; 2002; 62(4):655-703. PubMed ID: 11893234 [TBL] [Abstract][Full Text] [Related]
18. Paroxetine: a review of clinical experience. Dunner D; Kumar R Pharmacopsychiatry; 1998 May; 31(3):89-101. PubMed ID: 9657236 [TBL] [Abstract][Full Text] [Related]